A phase 1/2 study of ONCT-534, a dual-action androgen receptor inhibitor (DAARI), in patients with metastatic castration-resistant prostate cancer.

被引：1
|
作者：
Yu, Evan Y.
Yazji, Salim
Katz, Yisrael
Coates, Elisabeth
Nordquist, Luke T.
Vandross, Andrae Lavon
Salkeni, Mohamad Adham
Lang, Joshua Michael
Nelson, Peter
Breitmeyer, James Bradley
Fong, Lawrence
De Bono, Johann S.
机构：
[1] Fred Hutchinson Canc Res Ctr, Seattle, WA USA
[2] Oncternal Therapeut Inc, San Diego, CA USA
[3] Urol Canc Ctr PC, Omaha, NE USA
[4] NEXT Oncol, Austin, TX USA
[5] NEXT Oncol, Fairfax, VA USA
[6] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA
[7] Univ Calif San Francisco, Div Hematol & Oncol, San Francisco, CA USA
[8] Royal Marsden Hosp NHS Fdn Trust, London, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 4_SUPPL期
关键词：
613-225-3248-4005; 283-183-180-5577-2829-12292; 613-225-325; 261-436; 130-540-543; 283-183-180; 298-145-222-184-1022-9124; 7; 5; 4; 3; 2; 60; 2946; 1917; 162; 1; 38092-18135; 38092-18313; 38092-21759; 9;
D O I：
10.1200/JCO.2024.42.4_suppl.TPS241
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：TPS241 / TPS241
页数：1
相关论文
共 50 条
  • [31] Predictive Significance of Androgen Receptor Splice Variant 7 in Patients With Metastatic Castration-Resistant Prostate Cancer: The PROPHECY Study
    Dirix, Luc
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (24) : 2180 - +
  • [32] Phase 1 efficacy and pharmacodynamic results of exicorilant plus enzalutamide in patients with metastatic castration-resistant prostate cancer.
    Morris, Michael J.
    Linch, Mark David
    Crabb, Simon J.
    Beer, Tomasz M.
    Heath, Elisabeth I.
    Gordon, Michael S.
    De Bono, Johann S.
    Pashova, Hristina I.
    Tudor, Iulia Cristina
    Greenstein, Andrew E.
    Mann, Grace
    Liu, Glenn
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [33] Androgen receptor mutations in patients with castration-resistant prostate cancer treated with apalutamide
    Rathkopf, D. E.
    Smith, M. R.
    Ryan, C. J.
    Berry, W. R.
    Shore, N. D.
    Liu, G.
    Higano, C. S.
    Alumkal, J. J.
    Hauke, R.
    Tutrone, R. F.
    Saleh, M.
    Maneval, E. Chow
    Thomas, S.
    Ricci, D. S.
    Yu, M. K.
    de Boer, C. J.
    Trinh, A.
    Kheoh, T.
    Bandekar, R.
    Scher, H. I.
    Antonarakis, E. S.
    ANNALS OF ONCOLOGY, 2017, 28 (09) : 2264 - 2271
  • [34] Oral EPI-7386 in patients with metastatic castration-resistant prostate cancer.
    Pachynski, Russell Kent
    Iannotti, Nicholas
    Laccetti, Andrew Leonard
    Carthon, Bradley Curtis
    Chi, Kim N.
    Smith, Matthew Raymond
    Vogelzang, Nicholas J.
    Tu, Wilson
    Kwan, Edmond Michael
    Wyatt, Alexander William
    Villaluna, Karen
    Younginger, Brett
    Cesano, Alessandra
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [35] A phase 2 study of immunogenic cell death inducer PT-112 in patients with metastatic castration-resistant prostate cancer.
    Bryce, Alan Haruo
    Karp, Daniel D.
    Tagawa, Scott T.
    Nordquist, Luke T.
    Rathkopf, Dana E.
    Adra, Nabil
    Dorff, Tanya B.
    Baeck, Johan
    O'Donnell, Joseph Francis
    Ames, Tyler David
    Yim, Christina Y.
    Price, Matthew
    Scher, Howard I.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [36] Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate cancer
    Michaelson, M. D.
    Bellmunt, J.
    Hudes, G. R.
    Goel, S.
    Lee, R. J.
    Kantoff, P. W.
    Stein, C. A.
    Lardelli, P.
    Pardos, I.
    Kahatt, C.
    Nieto, A.
    Cullell-Young, M.
    Lewis, N. L.
    Smith, M. R.
    ANNALS OF ONCOLOGY, 2012, 23 (05) : 1234 - 1240
  • [37] Genomic Profiling of Metastatic Castration-Resistant Prostate Cancer Samples Resistant to Androgen Receptor Pathway Inhibitors
    Menssouri, Naoual
    Poiraudeau, Loic
    Helissey, Carole
    Bigot, Ludovic
    Sabio, Jonathan
    Ibrahim, Tony
    Pobel, Cedric
    Nicotra, Claudio
    Ngo-Camus, Maud
    Lacroix, Ludovic
    Rouleau, Etienne
    Tselikas, Lambros
    Chauchereau, Anne
    Blanc-Durand, Felix
    Bernard-Tessier, Alice
    Patrikidou, Anna
    Naoun, Natacha
    Flippot, Ronan
    Colomba, Emeline
    Fuerea, Alina
    Albiges, Laurence
    Lavaud, Pernelle
    van de Wiel, Paul
    den Biezen, Eveline
    Wesseling-Rozendaal, Yvonne
    Ponce, Santiago
    Michiels, Stefan
    Massard, Christophe
    Gautheret, Daniel
    Barlesi, Fabrice
    Andre, Fabrice
    Besse, Benjamin
    Scoazec, Jean-Yves
    Friboulet, Luc
    Fizazi, Karim
    Loriot, Yohann
    CLINICAL CANCER RESEARCH, 2023, 29 (21) : 4504 - 4517
  • [38] A phase II study of the androgen signaling inhibitor ARN-509 in patients with castration-resistant prostate cancer (CRPC)
    Rathkopf, Dana E.
    Shore, Neal
    Antonarakis, Emmanuel S.
    Berry, William R.
    Alumkal, Joshi J.
    Tutrone, Ronald
    Saleh, Mansoor N.
    Redfern, Charles H.
    Hauke, Ralph J.
    Liu, Glenn
    Steinbrecher, Jill Elise
    Danila, Daniel Costin
    Curley, Tracy
    Arauz, Gabrielle
    Rix, Peter J.
    Maneval, Edna Chow
    Chen, Isan
    Scher, Howard I.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [39] Dual targeting of EZH2 and androgen receptor as a novel therapy for castration-resistant prostate cancer
    Shankar, Eswar
    Franco, Daniel
    Iqbal, Omair
    Moreton, Stephen
    Kanwal, Rajnee
    Gupta, Sanjay
    TOXICOLOGY AND APPLIED PHARMACOLOGY, 2020, 404
  • [40] DUAL TARGETING OF EZH2 AND ANDROGEN RECEPTOR SYNERGISTICALLY INHIBITS CASTRATION-RESISTANT PROSTATE CANCER
    Shankar, Eswar
    Franco, Daniel
    Iqbal, Omair
    Moreton, Stephan
    Kanwal, Rajnee
    Gupta, Sanjay
    JOURNAL OF UROLOGY, 2019, 201 (04): : E495 - E495
12345